Summary & Overview
HCPCS Level II J1030: Methylprednisolone Acetate Injection, 40 mg
HCPCS Level II code J1030 denotes a 40 mg injection of methylprednisolone acetate, a corticosteroid widely used for anti-inflammatory and immunosuppressive indications. This code matters nationally because it standardizes billing for a commonly used injectable medication across outpatient and ambulatory settings and influences pharmacy and procedural billing workflows.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical role and the typical sites of service where it is applied. The publication outlines what to expect in payer coverage patterns and benchmarks, summarizes relevant policy considerations that affect reimbursement for injectable drugs, and situates the code within clinical use for inflammatory and immune-mediated conditions.
This analysis provides operational context for billing teams, revenue cycle staff, and clinicians involved in ordering or administering injectable corticosteroids. Data not available in the input is noted where applicable; the document focuses on code definition, payer inclusion, and the types of benchmarks and policy updates readers can expect to find in the full publication.
Billing Code Overview
HCPCS Level II code J1030 represents an injection of methylprednisolone acetate, 40 mg. This entry is used to bill for the drug product administered by injection and is typically classified as a parenteral drug administration service.
-
Service type: Injection of a corticosteroid medication for anti-inflammatory or immunosuppressive effect
-
Typical site of service: Physician office, outpatient clinic, or other ambulatory settings where injectable medications are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a middle-aged adult presenting to an outpatient orthopedics or pain-management clinic with focal joint or periarticular pain from inflammatory or degenerative conditions such as osteoarthritis, bursitis, or tendinopathy. After history, targeted physical exam, and imaging review (for example, radiographs or ultrasound confirming joint degeneration or effusion), the clinician plans an intra-articular or soft-tissue corticosteroid injection for symptomatic relief. The clinician documents indication, informed consent, allergies, and anticoagulation status. The procedure is commonly performed in an ambulatory clinic procedure room, orthopedic office, or ambulatory surgery center using sterile technique. Local anesthesia may be provided; image guidance (ultrasound or fluoroscopy) is sometimes used for accuracy. The medication administered is methylprednisolone acetate 40 mg (J1030) delivered as a single injection into the affected joint or periarticular site. Post-procedure monitoring includes brief observation for immediate adverse reactions, post-injection instructions, and documentation of lot number and expiration for the drug.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when reporting only the physician's professional portion of a bundled service when applicable to the visit or image-guided procedure component. |